LGM Pharma is a Abciximab CAS# 143653-53-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
Questions? Call our customer API support number 1-(800)-881-8210.
LGM Pharma offers this active ingredient but not the finished dosage forms.
CAS No: 143653-53-6
AHFC code: 32:00.0
Synonyms: 7E3 antibody antiGPIIBIIIa c7E3 ReoPro
ATC Code: B01AC13
Chemical Formula: C20H34O5
Molecular Weight: 145651.1
Assay/Purity: Typically NLT 98%
DrugBank: DB00054 (BIOD00041, BTD00041)
Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.
Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. GPIIb/IIIa is the major surface receptor involved in the final pathway of platelet aggregation. Abciximab is thought to proclude GPIIb/IIIa substrate binding via steric hindrance and/or conformational effects rather than by direct interaction with the arginine-glycine-aspartic acid binding site of the receptor.
Mode of Action:
Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPIIb/IIIa.
Most likely removed by opsonization via the reticuloendothelial system when bound to platelets, or by human antimurine antibody production. Excreted renally.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
API’s From Quality Manufacturers:
Cost effective materials based on specific requirements
Small quantities for initial research and larger development quantities towards product commercialization
Technical packages, letters of access to filed DMFs